21.01.2025
Egnach, January 21, 2025 – Work is now starting on the double-blind study on the tinniwell. In the first step, the software is adapted, and, after successful testing, a second clinical user observation is carried out with the same design of the double-blind study. After the work has been successfully completed, the final study will be started immediately.
++ About Resaphene Suisse AG
Resaphene Suisse AG, based in Egnach, Switzerland, is a medical technology company that was founded in 2015 and has been selling a tinnitus therapy device under the name tinniwell since 2016.
++ Contact for questions:
Resaphene Suisse AG
Mrs. Anke Rauterkus (Chief Executive Officer)
Bahnhofplatz 5
9322 Egnach
Switzerland
T. +41 714500668
a.rauterkus@resaphene.ch
Back